Treatment of hypothalamic obesity with caffeine and ephedrine

Endocrine Practice

Volumn 14, Issue 6, 2008, Pages 697-703

  Greenway, Frank L ^a   Bray, George A ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; EPHEDRINE; ANTIOBESITY AGENT;

ADOLESCENT; ADULT; ARTICLE; BARIATRIC SURGERY; CASE REPORT; DRUG DOSE INCREASE; FEMALE; HUMAN; HYPOTHALAMUS; METABOLIC RATE; OBESITY; SYMPATHETIC TONE; TREATMENT OUTCOME; WEIGHT REDUCTION; HYPOTHALAMUS DISEASE;

ADOLESCENT; ADULT; ANTI-OBESITY AGENTS; CAFFEINE; EPHEDRINE; FEMALE; HUMANS; HYPOTHALAMIC DISEASES; OBESITY;

EID: 64749097994     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.6.697     Document Type: Article

References (31)

1. Meuric S, Brauner R, Trivin C, Souberbielle JC, Zerah M, Sainte-Rose C. Influence of tumor location on the presentation and evolution of craniopharyngiomas. J Neurosurg. 2005;103(5 suppl):421-426.
2. Fröhlich A. Ein Fall von Tumor der Hypophysis cerebri ohne Akromegalie. Weiner Klin Rdsch. 1901;15:883-886.
3. Bruch H. The Fröhlich syndrome: report of the original case. Am J Dis Child. 1939;58:1281-1289.
4. Babinski M. Tumeur du corps pituitaire sans acromegalie et avec arret de developpement des organes genitaux. Rev Neurol. 1900;8:531-533.
5. Erdheim J. Uber Hypophysenganggeschwülste und Hirncholesteatome. Sitzungsb Akad Wissenchafften (Wein). 1904;113:537-726.
6. Bray GA, Gallagher TF Jr. Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine (Baltimore). 1975;54:301-330.
7. Reeves AG, Plum F. Hyperphagia, rage, and dementia accompanying a ventromedial hypothalamic neoplasm. Arch Neurol. 1969;20:616-624.
8. Brauner R, Trivin C, Zerah M, et al. Diencephalic syndrome due to hypothalamic tumor: a model of the relationship between weight and puberty onset. J Clin Endocrinol Metab. 2006;91:2467-2473.
9. Bray GA. Genetic, hypothalamic and endocrine features of clinical and experimental obesity [with discussion]. Prog Brain Res. 1992;93:333-341.
10. Perkins MN, Rothwell NJ, Stock MJ, Stone TW. Activation of brown adipose tissue thermogenesis by the ventromedial hypothalamus. Nature. 1981;289:401-402.
11. King BM. The rise, fall, and resurrection of the ventromedial hypothalamus in the regulation of feeding behavior and body weight. Physiol Behav. 2006;87:221-244.
12. King BM, Frohman LA. The role of vagally-mediated hyperinsulinemia in hypothalamic obesity. Neurosci Biobehav Rev. 1982;6:205-214.
13. Inoue S, Bray GA. The effects of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic obesity. Endocrinology. 1977;100:108-114.
14. Berthoud HR, Niijima A, Sauter JF, Jeanrenaud B. Evidence for a role of the gastric, coeliac and hepatic branches in vagally stimulated insulin secretion in the rat. J Auton Nerv Syst. 1983;7:97-110.
15. Tokunaga K, Fukushima M, Kemnitz JW, Bray GA. Effect of vagotomy on serum insulin in rats with para-ventricular or ventromedial hypothalamic lesions. Endocrinology. 1986;119:1708-1711.
16. Sakaguchi T, Bray GA, Eddlestone G. Sympathetic activity following paraventricular or ventromedial hypothalamic lesions in rats. Brain Res Bull. 1988;20:461-465.
17. Niijima A, Rohner-Jeanrenaud F, Jeanrenaud B. Role of ventromedial hypothalamus on sympathetic efferents of brown adipose tissue. Am J Physiol. 1984;247(4, pt 2): R650-R654.
18. Vander Tuig JG, Knehans AW, Romsos DR. Reduced sympathetic nervous system activity in rats with ventromedial hypothalamic lesions. Life Sci. 1982;30:913-920.
19. Yoshida T, Bray GA. Catecholamine turnover in rats with ventromedial hypothalamic lesions. Am J Physiol. 1984; 246(4, pt 2):R558-R565.
20. Jeanrenaud B. Energy fuel and hormonal profile in experimental obesities. Experientia Suppl. 1983;44:57-76.
21. York DA, Bray GA. Dependence of hypothalamic obesity on insulin, the pituitary and the adrenal gland. Endocrinology. 1972;90:885-894.
22. Lustig RH, Rose SR, Burghen GA, et al. Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr. 1999;135(2, pt 1):162-168.
23. Boosalis MG, Gemayel N, Lee A, Bray GA, Laine L, Cohen H. Cholecystokinin and satiety: effect of hypothalamic obesity and gastric bubble insertion. Am J Physiol. 1992;262(2, pt 2):R241-R244.
24. Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev. 2001;2:199-211.
25. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet: a double blind trial. Int J Obes Relat Metab Disord. 1992;16:269-277.
26. World Health Organization. Diet, nutrition and the prevention of chronic diseases: report of a WHO study group. WHO Tech Rep Ser. 1990:797.
27. Astrup A, Buemann B, Christensen NJ, et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism. 1992;41: 686-688.
28. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. Int J Obes Relat Metab Disord. 1993; 17(suppl 1):S35-S40.
29. Knowler WC, Barrett-Connor E, Fowler SE, et al (Diabetes Prevention Program Research Group). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
30. Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586-2592.
31. Lustig RH, Greenway F, Velasquez-Mieyer P, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion. Int J Obes (Lond). 2006;30:331-341.